October 19, 2017 / 1:44 PM / a year ago

BRIEF-Roche drugs chief says Ocrevus uptake to vary across countries

Oct 19 (Reuters) - Roche Holding Ag

* CFO expects no impact from currencies on 2017 sales, core operating profit or eps

* Drugs chief Dan O’Day says not ‘pulling back’ on impower 150 trial expectations, still awaiting data

* Drugs chief O’Day says remains bullish for ACE910 for non-inhibitor haemophilia population

* Drugs chief says expects tecentriq sales to grow following european approval

* O’Day says having good dialogue with regulatory authorities on ocrevus, expects positive chmp opinion before year’s end

* Drugs chief says Ocrevus uptake in Europe will vary from country to country, cannot compare with U.S. uptake Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below